VMX-C001 + rivaroxaban

**VMX-C001 + rivaroxaban** refers to the combination of an engineered recombinant human coagulation factor X (named VMX-C001) and the direct oral anticoagulant rivaroxaban. - **VMX-C001** is a **modified recombinant human coagulation factor X** designed to resist inhibition by factor Xa (FXa) direct oral anticoagulants (DOACs), such as rivaroxaban. VMX-C001 serves as a **bypassing agent**, restoring coagulation in patients with serious bleeding or requiring urgent surgery who are on FXa DOACs. It is given intravenously and works by obstructing the DOAC binding site on factor Xa, allowing coagulation even in the presence of DOACs. - **Rivaroxaban** is a small molecule **oral direct factor Xa inhibitor** used as an anticoagulant to prevent and treat thromboembolic disorders. This combination is being studied for scenarios like emergency reversal of anticoagulation to restore hemostasis after rivaroxaban exposure. VMX-C001 is under clinical development by VarmX, with Phase 1 studies demonstrating safety, pharmacokinetics, and proof of mechanism for rapid DOAC reversal in healthy subjects and relevant animal models[1][2][3][4][5][6].